相关实验视频
Updated: May 30, 2025

09:03
The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice
Published on: February 3, 2012
19.1K
在自身免疫性肝炎中,对阿扎西奥普林治疗的反应取决于谷氨转移酶基因型
Malin Lindqvist Appell1, Ulf Hindorf2, Sven Almer3
1Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.
概括
谷氨转移酶基因变异 (GSTM1和GSTT1 CNV) 影响了在自身免疫性肝炎 (AIH) 中阿扎西奥普林 (AZA) 治疗的有效性. 这些遗传因素影响肝酶水平,但不影响代谢物度,突出显示了AZA有效性中的非酶作用.
科学领域:
- 药物基因组学 药物基因组学
- 肝病学 肝病学是一种肝病学.
- 免疫学 免疫学 免疫学
背景情况:
- 阿扎西奥普林 (AZA) 是一种针对自身免疫性肝炎 (AIH) 的标准疗法.
- 谷氨转移酶 (GSTs) 对于AZA初始生物转化为其活性代谢物至关重要.
- 了解对AZA代谢的遗传影响可以优化AIH治疗.
研究的目的:
- 调查GSTM1和GSTT1的副本数变异 (CNV) 和GSTA2,GSTP1和 inosine-triphosphate-pyrophosphatase的遗传变异与AIH患者的AZA治疗反应之间的关联.
- 探索这些遗传因素与硫氨酸代谢物水平之间的关系.
主要方法:
- 对接受AZA的131名AIH患者和来自瑞典背景人口的283人进行了基因型鉴定.
- 使用高性能液体色谱测定血红细胞中硫氨酸代谢物度.
- 分析的重点是关键GST基因中的副本数变异 (CNV) 和单核酸多态 (SNP).
主要成果:
- GSTM1和GSTT1 CNV与AIH患者对AZA的治疗反应有显著的相关性.
- 删除GSTM1基因,但不删除GSTT1,与肝脏转氨酶水平的改变相关.
- 没有研究过的遗传变异显示与硫氨酸代谢物度的关联,这表明GSTM1和GSTT1在AZA疗效中的非酶作用.
- 在AIH患者和一般人群中,GSTM1和GSTT1 CNV基因型的患病率一致.
结论:
- GSTM1和GSTT1 CNVs影响自身免疫性肝炎中的AZA疗效,这一发现以前没有得到很好的描述.
- 该研究强调了考虑特定的GST基因变异和AIH管理中治疗反应的定义的重要性.
- 在欧洲人群中证实了GSTM1和GSTT1 CNV的以前报告的频率.
相关概念视频
Phase II Reactions: Glutathione Conjugation and Mercapturic Acid Formation
135
Glutathione, a tripeptide made up of glutamate, cysteine, and glycine, is a critical player in the detoxification of drugs and xenobiotics via a process known as glutathione conjugation or mercapturic acid formation. This phase II biotransformation reaction involves the covalent binding of glutathione to a drug or its metabolite, enhancing the compound's water solubility and enabling its excretion.
Several distinctive characteristics distinguish glutathione conjugation from other phase II...
Several distinctive characteristics distinguish glutathione conjugation from other phase II...
135
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
141
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
141
Autoimmune Disorders
380
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...
Concept and Mechanism of Autoimmune Diseases
The immune...
380
Myasthenia Gravis: Overview and Treatment
1.1K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.1K
Phase II Reactions: Glucuronidation
255
Glucuronidation, a pivotal phase II biotransformation process, involves the coupling of glucuronic acid to a drug or xenobiotic. Given its widespread occurrence and critical role in drug metabolism, it's considered the most crucial phase II reaction. It enhances the water solubility of substances, aiding their expulsion from the body. The driving force behind these reactions is a group of enzymes known as UDP-glucuronosyltransferases (UGTs). UGTs facilitate the transfer of a glucuronic acid...
255
Drug Metabolism: Phase II Reactions
3.6K
Phase II reactions are essential for the detoxification and elimination of drugs from the body. These reactions involve the conjugation of parent drugs or their phase I metabolites with endogenous molecules, resulting in more hydrophilic drug conjugates. The primary conjugation reactions in this phase are sulfation and glucuronidation. Both sulfation and glucuronidation typically produce biologically inactive metabolites. However, in some cases involving prodrugs, active metabolites may be...
3.6K

